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Background. IgA nephropathy (IgAN) runs a highly variable
clinical course, with frequent involvement of tubulointerstitial
damage. A subgroup of IgAN with severe tubulointerstitial
damage is often associated with the most rapid progression to
end-stage renal failure. In IgAN, mesangial sclerosis and tubu-
lointerstitial damage were found to be correlated with the in-
crease in pore size of the glomerular barrier.
Methods. The direct toxicity of proximal tubular epithelial
cells (PTEC) by IgA in IgAN is still unresolved. Activation of
PTEC by mediators released from infiltrating cells or resident
kidney cells that induce tubular inflammation is the common
final pathway in most chronic renal diseases. We hypothesize
that mediators released from human mesangial cells (HMC)
triggered by IgA deposition may lead to PTEC activation.
Results. We found that IgA binding to PTEC was less than
one tenth that of HMC. The binding was nonspecific and ex-
hibited no increased cell proliferation or enhanced synthesis of
cytokines or adhesion molecules. However, when PTEC were
cultured with IgA-HMC spent medium prepared from IgAN
patients, there was enhanced proliferation of PTEC and in-
creased synthesis of cytokines and adhesion molecules.
Conclusion. These findings implicate a glomerulotubular
cross-talk with mediators released from the mesangium, con-
tributing to the pathogenesis of tubulointerstitial damage in
IgAN. There are preliminary data to suggest that the expres-
sion of angiotensin II subtype-1 receptor and angiotensin II
subtype-2 receptor in PTEC differs from that of HMC. These
novel findings may provide clinicians new therapeutic approach
for selective blockade of the tubulointerstitial injury in IgAN.
IgA nephropathy (IgAN), the most common primary
glomerulonephritis worldwide, is associated with a sub-
stantial risk of progression to end-stage renal failure
(ESRF) [1]. Proteinuria is a well-recognized risk factor
for progression in different glomerular diseases. How-
ever, the prognostic value of high-grade proteinuria is
more complicated in IgAN. First, heavy proteinuria is not
common in IgAN [2]; nephrotic syndrome, an unusual
presenting symptom, occurs in only 5% of all IgAN [3].
Second, it has been reported that the severity of protein-
uria may not always bear any significant correlation with
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the severity of renal histopathologic changes [4, 5]. One
of the possible explanations is the existence of a variant
of IgAN associated with a nephrotic syndrome that re-
sembles lipoid nephrosis in its responsiveness to steroid
[6].
Certain clinical, laboratory, and pathologic parameters
have been identified as predictors of poor outcome in
IgAN. These include older onset of disease, arterial hy-
pertension, high glomerular histopathologic scores, the
extent of global glomerular and interstitial sclerosis, tubu-
lointerstitial fibrosis, persistent microscopic hematuria,
nephrotic-range proteinuria, and renal insufficiency at
the time of first diagnosis [7, 8]. These factors are con-
cluded from retrospective analysis of large cohorts of
patients. Indeed, for most patients with IgAN, these prog-
nostic indicators are weak on an individual basis. Notably,
most nephrologists observed renal progression correlates
more closely with the severity of tubulointerstitial lesions
than with the degree of glomerular lesions [9, 10]. With
marked tubular atrophy, the remaining time to ESRF was
3.5 ± 2.7 for those with and 8.2 ± 4.2 years for those
without [11]. In addition, infiltration of circulating inflam-
matory cells, including mononuclear and polymorphonu-
clear leukocytes, to the renal interstitium is one of the
early and prominent histopathologic changes preceding
the induction of glomerular or tubulointerstitial injury.
Inflammation elicited by these infiltrating cells plays an
important role in subsequent development of glomerular
and tubulointerstitial damage [12].
WHAT LEADS TO TUBULOINTERSTITIAL
CHANGES: PROTEINURIA,
MONOCYTIC/MACROPHAGE INFILTRATION,
TUBULAR IGA DEPOSITION, OR OTHER
MECHANISMS?
The pathogenetic cascade of IgAN can be conveniently
divided into 3 phases: (1) synthesis of “pathogenetic
IgA;” (2) mesangial IgA deposition and mesangial in-
flammatory injury; and (3) tubulointerstitial injury. While
the pathogenetic significances of abnormal glycosylation
of the IgA molecule and the mesangial binding of IgA
via known IgA receptors still remain unclear, IgA de-
posited in the mesangium clearly induces local release
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of cytokines, complement, and angiotensin II (Ang II),
leading to inflammatory injury [3, 13]. The question that
has not been explored is how would mesangial IgA de-
position lead to tubulointerstitial injury in IgAN? Four
pathogenetic mechanisms of tubulointerstitial injury
may operate independently or synergistically, namely:
monocytic/macrophage infiltration, proteinuria, direct
inflammatory effect of IgA, and a glomerulotubular
cross-talk.
The involvement of infiltrating inflammatory cells in
the tubulointerstitium is important in mediating tubular
injury and renal fibrosis [14]. As a consequence, resident
kidney cells can become activated during the inflamma-
tory process. In recent years, much attention has focused
on the role of proximal tubular epithelial cells (PTEC)
in orchestrating the infiltration of inflammatory cells and
the renal fibrosis via production of inflammatory medi-
ators upon activation. Mediators released by infiltrating
cells are directly responsible for the activation of PTEC,
which, in turn, may amplify the inflammatory cascade by
local production of chemotactic mediators that attract
even more inflammatory competent cells. The outcome
of such a chain reaction is the generation of a positive
feedback loop of activation that may lead to the overpro-
duction of extracellular matrix components, resulting in
fibrosis and ultimately loss of kidney function. Therefore,
a cytokine “cross-talk” network between PTEC and in-
terstitial immunocompetent cells can be envisaged to be
the major driving force of tubulointerstitial injury. The
key role of tubular epithelial cells in progressive renal
diseases have been reviewed, and collective data from the
literature have clearly demonstrated the ability of tubular
epithelial cells in producing a wide variety of inflamma-
tory mediators [15]. Proteinuria is the major stimulus of
PTEC activation and subsequent chemotaxis of infiltrat-
ing immunocompetent cells in most glomerular diseases
[16]. Our novel finding that “conditioned” supernatant
from PTEC stimulates the proliferation of mesangial
cells provides experimental evidence to suggest a tubu-
loglomerular “cross-talk” mechanism, involving different
soluble factors, is likely to operate in different glomerular
and interstitial nephritis [17]. However, proteinuria may
be one of the several contributory factors in tubulointer-
stitial injury in IgAN because heavy or nephrotic-range
proteinuria is uncommon [2, 3].
The other possible contributory factor is the direct
toxic effect following tubular binding of IgA. IgAN pa-
tients have increased urinary IgA concentration that cor-
relates with serum creatinine concentration, as well as the
urinary protein excretion [18]. By immunofluorescence,
tubulointerstitial deposits were previously reported in
10% to 35% of proximal tubules, consisting of C3 in
all, and IgA in 11% of IgAN patients in one study [19].
However, other investigators noted that IgA deposits are
rarely detected in the tubulointerstitium [20, 21]. The
scarcity of tubular IgA deposition in IgAN is illustrated
in Figure 1.
DOES URINARY IGA BIND TO TUBULAR
EPITHELIAL CELLS TO EXERT
INFLAMMATORY INJURY IN IgAN?
The increase in glomerular barrier pore size that al-
lowed the passage of proteins to the tubular lumen was
observed in various glomerular diseases [22]. Normally,
the glomerular barrier is impermeable to proteins. How-
ever, it is possible that the tubular lumen could be ex-
posed to the high-molecular-weight IgA from patients
with IgAN, especially when the glomerular size barrier
was impaired in IgAN [23]. Hence, it remains interest-
ing and important to ascertain in IgAN whether IgA is
capable of binding to PTEC, and to elicit similar inflam-
matory responses as those observed in human mesangial
cells (HMC).
Our preliminary data demonstrated that there was
minimal binding of IgA from IgAN patients to cultured
PTEC [24]. The amount of IgA binding to PTEC was
less than 10% that of mesangial cells. The representa-
tive immunofluoresence staining of IgA binding to HMC
or PTEC is shown in Figure 2. As for the expression of
documented IgA receptors in PTEC, there was absence
of known IgA receptors in cultured PTEC except the
transferrin receptor. Competitive binding assay of IgA
to PTEC using different ligands (including transferrin)
for known IgA receptors further confirms that known
IgA receptors were not expressed in PTEC. The lack of
cell proliferation and absence of inflammatory mediator
production from PTEC stimulated with IgA from IgAN
patients suggest that the low level of IgA bound to the
PTEC is a nonspecific binding in the cell culture experi-
ment. Our data support the previous observation that IgA
deposits are rarely detected in the tubulointerstitium in
IgAN [20].
HYPOTHESIS: A GLOMERULOTUBULAR
CROSS-TALK IN IgAN VIA HUMORAL FACTORS
Failing to demonstrate a specific binding of IgA to
PTEC and the infrequent occurrence of high-grade pro-
teinuria in IgAN, we postulate a new mechanism that
may be operative upon mesangial IgA deposition that
subsequently leads to tubulointerstitial atrophy and fibro-
sis in IgAN. It has been documented that inflammatory
cytokines, including Ang II, are released from mesan-
gial cells following binding to IgA in IgAN. We hypoth-
esize that these mediators alter the glomerular barrier
pore size that allows the passage of these inflammatory
mediators to the tubular lumen. These mediators then
activate the PTEC, which in turn may amplify the in-
flammatory cascade by local production of chemotactic
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Fig. 1. Representative immunohistologic staining in kidney biopsy from patients with IgAN. (A) Immunofluoresence study revealing mesangial
IgA deposition with IgA cast in tubular lumen (solid arrow) and absence of tubular IgA deposits (open arrow) (magnification ×400). (B) Im-
munoperoxidase study (visualized by the Dako Envision plus system) revealing mesangial IgA deposition and absence of tubular IgA deposits
(magnification ×400). (C) Immunoperoxidase study (visualized by the Dako Envision plus system) revealing mesangial and tubular deposition of
TGF-b (magnification ×250). (D) Immunoperoxidase study revealing no IgA deposition in control kidney tissue (magnification ×400).
mediators, which attract even more inflammatory com-
petent cells. This glomerulotubular cross-talk will gen-
erate a positive feedback loop of activation in the renal
tubules that leads to the overproduction of extracellular
matrix components, resulting in fibrosis and ultimately
loss of kidney function. We tested our hypothesis by con-
ducting an experiment in which PTEC was cultured with
spent medium prepared from mesangial cells incubated
with IgA from IgAN patients [24]. Contrary to the ab-
sent stimulatory effect on PTEC upon direct incubation
with IgA, we observed an increased proliferation and en-
hanced expression of inflammatory mediators (including
interleukin-6, tumor necrosis factor-a, soluble intercellu-
lar adhesion molecule-1, and Ang II) in PTEC cultured
with spent medium prepared from mesangial cells in-
cubated with IgA from IgAN patients. Tubular and in-
terstitial intercellular adhesion molecule-1–positive cells
may participate in adhesive interactions with interstitial
leukocytes [25]. Up-regulation of renal interleukin-6 ex-
pression correlates well to the degree of tubulointerstitial
damage in IgAN [26].
DIFFERENTIAL EXPRESSION OF ANG II
SUBTYPE-1 RECEPTOR (AT1R) AND ANG II
SUBTYPE-2 RECEPTOR (AT2R) IN MESANGIAL
CELLS AND TUBULAR EPITHELIAL CELLS
The renin-angiotensin system (RAS) is a key factor in
the progression of chronic renal failure. Ang II plays a
pivotal role as a mediator of glomerular hemodynamic
adaptation, and also in immunologic injury. We have
demonstrated that polymeric IgA (pIgA) from IgAN
patients up-regulates the synthesis and signal transduc-
tion of transforming growth factor-b in human mesan-
gial cell via the RAS by inducing the synthesis of Ang II
[15]. Pharmacologic blockade of this system, either
by angiotensin-converting enzyme (ACE) inhibitor or
AT1R antagonist, retards the progression of glomeru-
losclerosis [27]. Despite the presence of gene encoding
for renin, angiotensinogen, and ACE in renal mesangial
cells [28], little is known about the intrarenal RAS in
IgAN. Both AT1R and AT2R are expressed in the kidney
from healthy subjects and from patients with glomerular
disease [29]. The histologic distribution of these receptors










Fig. 2. Representative immunofluorescent staining of IgA binding to human mesangial cells (MC) and human proximal tubular epithelial cells
(PTEC). Binding of IgA from IgAN patients to HMC (C) was higher than that from healthy controls (CTL) (B). Binding of IgA from IgAN patients
(F) or healthy controls (E) to PTEC was barely detectable. No positive staining was observed in HMC (A) or PTEC (D) stained with isotype control
antibody (magnification ×400).
implicates that both receptor may have a physiologic role
in human normal and diseased kidneys.
Our recent studies on the mesangial expression of
AT1R and AT2R following the release of Ang II by pIgA
from patients with IgAN revealed a reduction of AT1R
expression after the acute exposure of the cells to pIgA
[30]. The initial down-regulation of AT1R expression
mirrors an adaptive response to high intrarenal Ang II
level in human glomerulonephritis, including IgAN. An
immediate down-regulation of mesangial AT1R expres-
sion will ameliorate the proliferative and inflammatory
changes. However, we found that such adaptive changes
might gradually be lost following prolonged exposure of
mesangial cells to pIgA in IgAN. The supernatant con-
centration of Ang II (10−11 to 10−10 mol/L) in HMC re-
leased by incubating with pIgA was too low to induce
apoptosis via activation of the AT2R. In contrast, similar
concentration of Ang II was able to stimulate AT1R ex-
pression and maintain proliferative activity. Hence, the
failure to suppress the AT1R expression continuously in
the presence of defective AT2R activation is likely to per-
mit the development of proliferative and inflammatory
processes in the glomerular mesangium that may perpet-
uate a glomerulotubular cross-talk that finally leads to
progression of renal deterioration in IgAN. More inter-
estingly, our preliminary data showed Ang II at a con-
centration of 10−10 mol/L is able to induce apoptosis in
PTEC, and this concentration is 10-fold lower than that in
a previous study [31]. We also observed an up-regulation
of gene expression of both AT1R and AT2R in PTEC cul-
tured with spent medium prepared from HMC incubated
with IgA from IgAN patients. These findings suggest a
differential expression of AT1R and AT2R in HMC and
PTEC in response to raised intrarenal Ang II concen-
tration following exposure to pIgA that may play a sig-
nificant role in the pathogenesis of IgAN. Interestingly,
in renal proximal tubular cells exposed to Ang II, the
growth-stimulatory effects through AT1R may be coun-
terbalanced by AT2R-mediated apoptosis and growth in-
hibition [32, 33].
PODOCYTES IN IgAN
Information of podocyte dysfunction in IgAN is ex-
tremely scarce. The concomitant observation of podocyte
loss and increasing disease severity in IgAN suggest that
podocyte loss is involved in causing or contributing to
the progressive proteinuria, glomerular sclerosis, and fil-
tration failure [34]. The analysis of podocyte injury by
morphometric analysis has provided additional prognos-
tic information in IgAN [35]. Recent data suggest a pro-
cess in which the elaboration of regulatory factors by
podocytes may play a direct role in the activation of
mesangial cell proliferation in IgAN [36]. An overex-
pression of Bcl-2 (death suppressor) protein observed
in early stages of IgAN may confer protection against
apoptotic injury to glomerular cells by counteracting
the opposing activities of Bax (death promotor) protein.
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Fig. 3. Schematic model of the variable mechanisms operating between the HMC, podocytes, and PTEC following mesangial IgA deposition in
the development of tubulointerstitial injury in progressive IgAN.
Table 1. New therapeutic options in reducing tubulointerstitial injury in IgAN
Target cells Mechanism Therapeutic options Reference





Decrease of Ang II release by IgA ACE inhibitor or AT1R antagonist [13]
Antagonism to the proliferative effect of PDGF PDGF antagonist—PDGF-B aptomer [38]
Podocyte Protection of apoptosis due to down-regulation of
Bcl-2 and up-regulation of Bax
Antiapoptotic action of peroxisome
proliferator-activated receptor alpha agonist
[39]
Tubular epithelial cell Reduce Ang II-induced renal vascular constriction Induction of cytochrome P450 2C23-mediated
epoxygenase activities—peroxisome
proliferator-activated receptor alpha activator
[40]
Induction of apoptosis and G1 phase arrest Peroxisome proliferator-activated receptor gamma
agonist—L-805645
[41]
Antagonizing the proliferative and
proinflammatory effect of AT1R expression
ACE inhibitor or AT1R antagonist [24]
Enhancing the antiproliferative and apoptotic effect
of AT2R expression
AT2R agonist—CGP-42112A, L-162,313 [43, 43]
Down-regulation of Bcl-2, associated with an increased
ratio of Bax/Bcl-2 by glomerular epithelial cells, corre-
lates with the severity of glomerulosclerosis. The issue of
how IgA affects podocyte function remains unknown and
deserves further study, as this will provide insight to other
pathogenetic mechanism of IgAN.
FUTURE THERAPEUTIC TARGETS FOR IgAN
Until now, there has been no effective or specific treat-
ment for IgAN. Reducing the rate of disease progression
is the main strategy in intervening the progression
of this nephropathy. Figure 3 summarizes the disease
mechanisms of IgAN revealed by recent studies. Be-
cause it remains difficult to target the upstream of
the pathogenetic cascade (i.e., synthesis of underglyco-
sylated IgA and blockade of specific IgA receptors),
attention is now focused in the downstream, aiming to
reduce the tubulointerstitial injury. This can potentially
be achieved at different cellular levels—mesangial bind-
ing of IgA, podocyte dysfunction leading to proteinuria
and glomerulosclerosis, and reduction of inflammatory
injury of tuberulointerstitium. The rationale and ther-
apeutic options are outlined in Table 1. Most of these
therapeutic options remain experimental or at the labo-
ratory levels, yet these novel directions represent a new
paradigm to intervene the progression of renal failure in
IgAN by reducing the tubulointerstital injury.
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